This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Docetaxel and Prednisone With or Without OGX-011 in Treating Patients With Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

This study has been completed.
Information provided by (Responsible Party):
Canadian Cancer Trials Group ( NCIC Clinical Trials Group ) Identifier:
First received: November 22, 2005
Last updated: September 27, 2011
Last verified: September 2011

RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. OGX-011 may help docetaxel and prednisone kill more tumor cells by making tumor cells less resistant to the drugs.

PURPOSE: This randomized phase II trial is studying how well giving docetaxel and prednisone with or without OGX-011 works in treating patients with recurrent or metastatic prostate cancer that did not respond to previous hormone therapy.

Condition Intervention Phase
Prostate Cancer Drug: custirsen sodium Drug: docetaxel Drug: prednisone Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Study of OGX-011 in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Hormone Refractory Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Canadian Cancer Trials Group ( NCIC Clinical Trials Group ):

Primary Outcome Measures:
  • Prostate-specific antigen (PSA) response measured by Bubley criteria at completion of study [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Toxicity [ Time Frame: 2 years ]
  • Time to treatment failure [ Time Frame: 2 years ]

Enrollment: 82
Study Start Date: June 2005
Study Completion Date: January 2011
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: OGX011, Docetaxel and Prednisone Drug: custirsen sodium

640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)

Subsequent cycles:

weekly on days 1, 8, 15 (3 week cycles)

Drug: docetaxel
75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)
Drug: prednisone
5mg PO BID
Active Comparator: Docetaxel plus prednisone Drug: docetaxel
75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)
Drug: prednisone
5mg PO BID

Detailed Description:



  • Determine the efficacy, in terms of prostate-specific antigen response, of docetaxel and prednisone with or without OGX-011 in patients with hormone-refractory locally recurrent or metastatic prostate cancer.


  • Determine the objective response rate and duration in patients treated with these regimens.
  • Determine the safety and toxic effects of these regimens in these patients.
  • Determine the overall and progression-free survival of patients treated with these regimens.

OUTLINE: This is a multicenter, randomized, open-label study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive a loading dose of OGX-011 IV over 2 hours on days -7, -5, and -3. Patients then receive OGX-011 IV over 2 hours on days 1, 8, and 15, docetaxel IV over 1 hour on day 1, and oral prednisone twice daily on days 1-21. Treatment repeats every 3 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive docetaxel IV over 1 hour on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 3 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed adenocarcinoma of the prostate

    • Metastatic or locally recurrent disease
  • Not curable with standard therapy
  • Systemic chemotherapy is indicated, due to disease progression while receiving androgen-ablative therapy (i.e., hormone-refractory disease)

    • Disease progression is defined as development of new metastatic lesions OR ≥ 2 consecutive rises in prostate-specific antigen (PSA) over a reference value
    • Androgen ablative therapy must have included either medical or surgical castration

      • Castrate level of testosterone (≤ 1.7 nmol/L) required if treated with medical androgen ablation
    • Patients with documented disease progression while on peripheral antiandrogens must also have documented PSA progression after stopping antiandrogens
  • PSA ≥ 5 ng/mL
  • No known CNS metastases


Performance status

  • ECOG 0-2

Life expectancy

  • At least 12 weeks


  • Absolute granulocyte count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • No known bleeding disorder


  • PT and PTT or INR normal
  • Bilirubin normal
  • AST and ALT ≤ 1.5 times upper limit of normal (ULN)


  • Creatinine ≤ 1.5 times ULN


  • No significant cardiac dysfunction


  • Fertile patients must use effective contraception
  • No pre-existing peripheral neuropathy ≥ grade 2
  • No active, uncontrolled infection
  • No significant neurological disorder that would preclude study compliance
  • No history of other malignancies within the past 5 years except adequately treated nonmelanoma skin cancer



  • No prior chemotherapy except estramustine and recovered
  • No other concurrent chemotherapy

Endocrine therapy

  • See Disease Characteristics
  • At least 4 weeks since prior antiandrogens (6 weeks for bicalutamide)
  • Luteinizing hormone-releasing hormone (LHRH) agonist therapy must be continued* or restarted* during study treatment to maintain castrate levels of testosterone NOTE: *For patients receiving LHRH agonist therapy prior to study entry


  • At least 4 weeks since prior external beam radiotherapy except low-dose, nonmyelosuppressive radiotherapy

    • Must have had less than 25% of marrow irradiated
  • No prior strontium chloride Sr 89
  • No concurrent radiotherapy except low-dose, nonmyelosuppressive, palliative radiotherapy


  • At least 2 weeks since prior major surgery


  • At least 4 weeks since prior investigational agent
  • At least 4 weeks since prior anticancer therapy
  • No concurrent therapeutic anticoagulants except low-dose oral anticoagulants (i.e., 1 mg warfarin) or low molecular weight heparin
  • No other concurrent investigational agents
  • No other concurrent cytotoxic therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00258388

United States, Washington
University of Washington
Seattle, Washington, United States, 98109
Tom Baker Cancer Centre
Calgary, Canada, T2N 4N2
Cross Cancer Institute
Edmonton, Canada, T6G 1Z2
QEII Health Sciences Center
Halifax, Canada, B3H 1V7
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Canada, L8V 5C2
BCCA - Cancer Centre for the Southern Interior
Kelowna, Canada, V1Y 5L3
London Regional Cancer Program
London, Canada, N6A 4L6
CHUM - Hopital Notre-Dame
Montreal, Canada, H2L 4M1
Atlantic Health Sciences Corporation
Saint John, Canada, E2L 4L2
Odette Cancer Centre
Toronto, Canada, M4N 3M5
Univ. Health Network-Princess Margaret Hospital
Toronto, Canada, M5G 2M9
BCCA - Vancouver Cancer Centre
Vancouver, Canada, V5Z 4E6
CancerCare Manitoba
Winnipeg, Canada, R3E 0V9
Sponsors and Collaborators
NCIC Clinical Trials Group
Study Chair: Kim N. Chi, MD British Columbia Cancer Agency
  More Information

Responsible Party: NCIC Clinical Trials Group Identifier: NCT00258388     History of Changes
Other Study ID Numbers: I165
CDR0000450846 ( Other Identifier: PDQ )
Study First Received: November 22, 2005
Last Updated: September 27, 2011

Keywords provided by Canadian Cancer Trials Group ( NCIC Clinical Trials Group ):
adenocarcinoma of the prostate
recurrent prostate cancer
stage IV prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antineoplastic Agents, Hormonal processed this record on August 18, 2017